PT3125888T - Derivados de 2,4-tiazolidinadiona no tratamento de distúrbios do sistema nervoso central - Google Patents
Derivados de 2,4-tiazolidinadiona no tratamento de distúrbios do sistema nervoso centralInfo
- Publication number
- PT3125888T PT3125888T PT157134990T PT15713499T PT3125888T PT 3125888 T PT3125888 T PT 3125888T PT 157134990 T PT157134990 T PT 157134990T PT 15713499 T PT15713499 T PT 15713499T PT 3125888 T PT3125888 T PT 3125888T
- Authority
- PT
- Portugal
- Prior art keywords
- treatment
- nervous system
- central nervous
- system disorders
- thiazolidinedione derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382130 | 2014-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3125888T true PT3125888T (pt) | 2018-07-20 |
Family
ID=50513194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT157134990T PT3125888T (pt) | 2014-04-02 | 2015-04-01 | Derivados de 2,4-tiazolidinadiona no tratamento de distúrbios do sistema nervoso central |
| PT181735416T PT3388064T (pt) | 2014-04-02 | 2015-04-01 | Derivados de 2,4-tiazolidinediona no tratamento de distúrbios do sistema nervoso central |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT181735416T PT3388064T (pt) | 2014-04-02 | 2015-04-01 | Derivados de 2,4-tiazolidinediona no tratamento de distúrbios do sistema nervoso central |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9782395B2 (pt) |
| EP (2) | EP3125888B1 (pt) |
| JP (2) | JP6745726B2 (pt) |
| KR (1) | KR102418167B1 (pt) |
| CN (1) | CN106470991B (pt) |
| AU (1) | AU2015239112C1 (pt) |
| CA (1) | CA2943373C (pt) |
| CL (1) | CL2016002508A1 (pt) |
| CY (2) | CY1120454T1 (pt) |
| DK (2) | DK3388064T3 (pt) |
| EA (2) | EA202091120A3 (pt) |
| ES (2) | ES2872335T3 (pt) |
| HR (2) | HRP20180983T1 (pt) |
| HU (2) | HUE055351T2 (pt) |
| IL (1) | IL248037B (pt) |
| LT (2) | LT3125888T (pt) |
| MX (1) | MX2016012687A (pt) |
| NZ (1) | NZ725492A (pt) |
| PL (2) | PL3388064T3 (pt) |
| PT (2) | PT3125888T (pt) |
| SG (1) | SG11201608218QA (pt) |
| SI (2) | SI3388064T1 (pt) |
| WO (1) | WO2015150476A1 (pt) |
| ZA (1) | ZA201607286B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| AU2014236510A1 (en) * | 2013-03-14 | 2015-09-24 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| US10188639B2 (en) | 2014-01-15 | 2019-01-29 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| AU2015239112C1 (en) * | 2014-04-02 | 2020-08-20 | Minoryx Therapeutics S.L. | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| EA201991304A1 (ru) | 2016-12-01 | 2019-12-30 | Минорикс Терапьютикс С.Л. | 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-дион для лечения неалкогольной жировой болезни печени |
| CA3046744A1 (en) | 2016-12-23 | 2018-06-28 | Minoryx Therapeutics S.L. | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof |
| MX2020013181A (es) * | 2018-06-06 | 2021-02-26 | Minoryx Therapeutics S L | Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona. |
| SG11202012095XA (en) | 2018-06-06 | 2021-01-28 | Minoryx Therapeutics S L | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts |
| US11957670B2 (en) | 2018-06-06 | 2024-04-16 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases |
| KR20230035522A (ko) | 2020-04-30 | 2023-03-14 | 미노릭스 테라퓨틱스 에스.엘. | 폐 염증 및 간질성 폐 질병을 치료하기 위한 레리글리타존 |
| US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
| US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5441971A (en) | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
| KR100249988B1 (ko) * | 1991-04-11 | 2000-04-01 | 로렌스 티. 마이젠헬더 | 티아졸리딘디온 유도체, 그의 제조방법 및 용도 |
| WO1993022445A1 (en) * | 1992-05-05 | 1993-11-11 | The Upjohn Company | A process for producing pioglitazone metabolite |
| US5952509A (en) | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| EP1465627B1 (en) | 2001-12-21 | 2006-03-08 | SmithKline Beecham Corporation | DOSING REGIMEN FOR PPAR−GAMMA ACTIVATORS |
| US8993773B2 (en) | 2002-07-16 | 2015-03-31 | Cadila Healthcare Limited | Process to prepare pioglitazone via several novel intermediates |
| AU2003254146A1 (en) * | 2003-07-24 | 2005-03-07 | Case Western Reserve University | Methods for the treatment of parkinson's disease |
| ES2397944T3 (es) | 2006-03-16 | 2013-03-12 | Metabolic Solutions Development Company Llc | Análogos de tiazolidindiona |
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| MX2012006730A (es) * | 2009-12-15 | 2012-07-30 | Metabolic Solutions Dev Co Llc | Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxizoma (ppar) y combinaciones para tratamiento de enfermedades neurodegenerativas y otras enfermedades metabolicas. |
| US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
| US20150224120A1 (en) | 2011-09-14 | 2015-08-13 | Catherine Clelland | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| US8865747B2 (en) * | 2012-03-23 | 2014-10-21 | Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) | Pioglitazone for use in the treatment of adrenoleukodystrophy |
| US20140178456A1 (en) | 2012-08-30 | 2014-06-26 | Udaya Sankar Devanaboyina | Methods and compositions for treating type 2 diabetes and related conditions |
| AU2014236510A1 (en) | 2013-03-14 | 2015-09-24 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| US10188639B2 (en) | 2014-01-15 | 2019-01-29 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| AU2015239112C1 (en) * | 2014-04-02 | 2020-08-20 | Minoryx Therapeutics S.L. | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
-
2015
- 2015-04-01 AU AU2015239112A patent/AU2015239112C1/en active Active
- 2015-04-01 KR KR1020167030649A patent/KR102418167B1/ko active IP Right Grant
- 2015-04-01 SI SI201531591T patent/SI3388064T1/sl unknown
- 2015-04-01 PL PL18173541T patent/PL3388064T3/pl unknown
- 2015-04-01 PT PT157134990T patent/PT3125888T/pt unknown
- 2015-04-01 CA CA2943373A patent/CA2943373C/en active Active
- 2015-04-01 EA EA202091120A patent/EA202091120A3/ru unknown
- 2015-04-01 ES ES18173541T patent/ES2872335T3/es active Active
- 2015-04-01 DK DK18173541.6T patent/DK3388064T3/da active
- 2015-04-01 PT PT181735416T patent/PT3388064T/pt unknown
- 2015-04-01 EP EP15713499.0A patent/EP3125888B1/en active Active
- 2015-04-01 NZ NZ725492A patent/NZ725492A/en unknown
- 2015-04-01 CN CN201580018404.6A patent/CN106470991B/zh active Active
- 2015-04-01 MX MX2016012687A patent/MX2016012687A/es active IP Right Grant
- 2015-04-01 LT LTEP15713499.0T patent/LT3125888T/lt unknown
- 2015-04-01 WO PCT/EP2015/057224 patent/WO2015150476A1/en active Application Filing
- 2015-04-01 EA EA201691997A patent/EA035866B1/ru unknown
- 2015-04-01 PL PL15713499T patent/PL3125888T3/pl unknown
- 2015-04-01 HU HUE18173541A patent/HUE055351T2/hu unknown
- 2015-04-01 JP JP2016560727A patent/JP6745726B2/ja active Active
- 2015-04-01 HU HUE15713499A patent/HUE039555T2/hu unknown
- 2015-04-01 SI SI201530325T patent/SI3125888T1/en unknown
- 2015-04-01 DK DK15713499.0T patent/DK3125888T3/en active
- 2015-04-01 ES ES15713499.0T patent/ES2678046T3/es active Active
- 2015-04-01 EP EP18173541.6A patent/EP3388064B1/en active Active
- 2015-04-01 LT LTEP18173541.6T patent/LT3388064T/lt unknown
- 2015-04-01 SG SG11201608218QA patent/SG11201608218QA/en unknown
-
2016
- 2016-05-05 US US15/147,484 patent/US9782395B2/en active Active
- 2016-09-26 IL IL248037A patent/IL248037B/en active IP Right Grant
- 2016-10-03 CL CL2016002508A patent/CL2016002508A1/es unknown
- 2016-10-21 ZA ZA2016/07286A patent/ZA201607286B/en unknown
-
2017
- 2017-10-05 US US15/725,950 patent/US10179126B2/en active Active
-
2018
- 2018-06-26 HR HRP20180983TT patent/HRP20180983T1/hr unknown
- 2018-07-23 CY CY20181100765T patent/CY1120454T1/el unknown
- 2018-12-13 US US16/218,829 patent/US20190255032A1/en not_active Abandoned
-
2020
- 2020-05-07 JP JP2020081949A patent/JP2020117539A/ja active Pending
-
2021
- 2021-03-30 HR HRP20210518TT patent/HRP20210518T1/hr unknown
- 2021-04-27 CY CY20211100363T patent/CY1124088T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210518T1 (hr) | Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava | |
| IL247841A0 (en) | Heterocyclic compounds for use in the treatment of disorders mediated by pi3k gamma | |
| IL258471A (en) | 11,13-modified saxitoxins for the treatment of pain | |
| IL256350A (en) | Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders | |
| PT3160464T (pt) | 6-hidroxibuspirona para uso no tratamento de transtornos do movimento | |
| HK1216641A1 (zh) | 用於治療σ受體相關疾病和病症的 -三唑- -胺 | |
| SI3452465T1 (sl) | Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni | |
| IL249502A0 (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases | |
| EP3507277B8 (en) | Hydroxynorketamine derivatives for the treatment of disorders | |
| DK3148588T3 (en) | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease | |
| PL3148990T3 (pl) | Związki tiazolidynonu i ich zastosowanie w leczeniu zaburzeń psychiatrycznych neurologicznych i stanów zapalnych, w szczególności stanów zapalnych układu nerwowego | |
| HRP20181123T1 (hr) | Spojevi 3,4-diamino-6-kloropirazin-2-karboksamida za liječenje bolesti posredovanih s enac | |
| PT3148990T (pt) | Compostos de tiazolidinona e seu uso no tratamento de condições psiquiátricas ou distúrbios neurológicos e inflamação, particularmente neuroinflamação | |
| GB201602011D0 (en) | Treating skin disorders | |
| TH1601002629A (th) | ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท | |
| GB201413533D0 (en) | Combination therapy for treating disorders of the vestibular system | |
| GB201416044D0 (en) | The way, Mental Health Therapeutic Technique |